Literature DB >> 10747282

A comparative analysis of the cost-effectiveness of treatment based on parasitological and symptomatic screening for Schistosoma mansoni in Burundi.

H Carabin1, H Guyatt, D Engels.   

Abstract

OBJECTIVES: To assess the cost-effectiveness of three alternative screening strategies in delivering treatment to patients presenting with symptoms suggestive of S. mansoni, using data collected from 17 PHCCs in the Rusizi Plain, Burundi. The three strategies were: (1) screening all symptomatic patients using a Kato-Katz smear and treating only the ones found positive; (2) treating all symptomatic patients or (3) treating only those presenting with symptoms of severe diarrhoea (blood in stool).
METHODS: The database consisted of 41 051 visits of symptomatic patients to the 17 PHCCs during 1990. Effectiveness was measured as the number of infected patients treated (gold standard: 25-mg Kato-Katz smear). Cost-effectiveness ratios (CERs) (cost in US$ per infected patient treated) were used to compare the control strategies. Sensitivity analysis was performed to assess the effect of drug price and prevalence of infection on the CERs.
RESULTS: The overall prevalence of S. mansoni infection was 9.5% (95% CI = 9.1%, 9.9%). Treating only those with severe symptoms of infection would have left 92% of infected patients untreated. Performing a Kato-Katz smear to confirm the diagnosis was more cost-effective than treating all symptomatic patients on a presumptive basis, with CERs of 4.2 US$ and 12.43 US$ per infected person treated, respectively. Sensitivity analysis showed that, for a cost of 0.99 US$ per dose of praziquantel, the Kato-Katz option remained the most cost-effective approach for prevalences under 76%. For a drug price of 0.21 US$ per dose, both strategies would have become equivalent. The latter value varied extensively per PHCC (range 0.17 US$ to 0.51 US$), due to the different prevalences of infection (range 0.5% to 34.3%).
CONCLUSION: We found that using severe diarrhoea as an indicator for infection was not appropriate, and that screening symptomatic patients with the Kato-Katz method remained the most cost-effective approach in the given setting. The CER of treating all symptomatic patients on a presumptive basis depended very much on the drug price and the endemic level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747282     DOI: 10.1046/j.1365-3156.2000.00530.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  11 in total

1.  Rapid assessment of Schistosoma mansoni: the validity, applicability and cost-effectiveness of the Lot Quality Assurance Sampling method in Uganda.

Authors:  Simon Brooker; Narcis B Kabatereine; Mark Myatt; J Russell Stothard; Alan Fenwick
Journal:  Trop Med Int Health       Date:  2005-07       Impact factor: 2.622

2.  Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.

Authors:  Gina S El-Feky; Wael S Mohamed; Hanaa E Nasr; Naglaa M El-Lakkany; Sayed H Seif El-Din; Sanaa S Botros
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 3.  Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam.

Authors:  Donald P McManus; Darren J Gray; Yuesheng Li; Zheng Feng; Gail M Williams; Donald Stewart; Jose Rey-Ladino; Allen G Ross
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Optimal survey designs for targeting chemotherapy against soil-transmitted helminths: effect of spatial heterogeneity and cost-efficiency of sampling.

Authors:  Hugh J W Sturrock; Peter W Gething; Archie C A Clements; Simon Brooker
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

5.  The global epidemiological situation of schistosomiasis and new approaches to control and research.

Authors:  D Engels; L Chitsulo; A Montresor; L Savioli
Journal:  Acta Trop       Date:  2002-05       Impact factor: 3.112

Review 6.  Economic evaluations addressing diagnosis and treatment strategies for neglected tropical diseases: an overview.

Authors:  Tália Machado de Assis; Ana Rabello; Gláucia Cota
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2021-05-24       Impact factor: 1.846

7.  Optimising cluster survey design for planning schistosomiasis preventive chemotherapy.

Authors:  Sarah C L Knowles; Hugh J W Sturrock; Hugo Turner; Jane M Whitton; Charlotte M Gower; Samuel Jemu; Anna E Phillips; Aboulaye Meite; Brent Thomas; Karsor Kollie; Catherine Thomas; Maria P Rebollo; Ben Styles; Michelle Clements; Alan Fenwick; Wendy E Harrison; Fiona M Fleming
Journal:  PLoS Negl Trop Dis       Date:  2017-05-26

8.  Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope.

Authors:  Hugo C Turner; Jaspreet Toor; T Déirdre Hollingsworth; Roy M Anderson
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

9.  The costs and cost-effectiveness of mass treatment for intestinal nematode worm infections using different treatment thresholds.

Authors:  Andrew Hall; Sue Horton; Nilanthi de Silva
Journal:  PLoS Negl Trop Dis       Date:  2009-03-31

10.  Magnetic beads for schistosomiasis diagnosis.

Authors:  Malcolm K Jones; Julie Balen
Journal:  PLoS Negl Trop Dis       Date:  2007-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.